| Akanda Corp. (NASDAQ: AKAN) is also positioning itself to be among the international first movers following the anticipated landmark change in US federal policy regarding CBPM.
It has been widely reported that the DEA plans to reclassify CB as a Schedule III substance as of April 30, 2024.
Akanda believes this rescheduling could reinvigorate capital markets and potentially lead to changes in NASDAQ and NYSE rules on listing plant-touching U.S. companies.
In response to these potential changes, Akanda has strategic plans to become a leader in consolidating US-based operators.
The company is closely monitoring the loosening of federal regulations and plans to explore potential strategies within the US market.
Akanda's board and management have extensive expertise in multiple global markets, including the United States, and are prepared to capitalize on these developments.
Key Market Insights
Germany: Pioneering Shops for Scientific Purposes Germany is progressing with the second pillar of its CBPM LGLization law by setting up municipal five-year pilot programs for state-controlled CBPM to be sold in licensed shops. The Ministry of Agriculture is drafting regulations focused on the "permission and monitoring of the use of CBPM for scientific purposes." This innovative approach underscores Germany's commitment to creating a structured and regulated market.
United Kingdom: Soaring Medical Sales The United Kingdom is experiencing unexpectedly high CBPM sales driven by unusually high per-patient consumption rates. A new report by Prohibition Partners reveals that by the end of 2024, approximately 62,960 patients in the UK will be using CBPM, generating sales of 240M eu-ros ($258.8M). This equates to an average annual consumption of 3,811 eur-os per patient, significantly higher than in Germany, where the average annual consumption per patient is 1,563 eur-os.
Akanda Corp. (NASDAQ: AKAN) is strategically positioned to capitalize on significant market potential in both Europe and the United States. With a robust portfolio, strategic partnerships, and a proactive approach to regulatory changes, Akanda is poised to become a leader in the global CBPM industry.
The company's focus on high-quality, affordable products and its commitment to improving access for patients and consumers underline its potential for sustained growth and success in the rapidly evolving CBPM market.
Here’s 7 reasons to immediately start your research on Akanda Corp. (NASDAQ: AKAN).
1. Under the Radar: As a nano-cap company with a market cap of less than $3M (as of 8/1/2024), Akanda Corp. (NASDAQ: AKAN) has a higher potential for growth compared to larger companies.
2. Ultra Low Float: With less than 1.9M shares in its float, Akanda Corp. (NASDAQ: AKAN). can experience significant price movements with shifts in demand, making it a stock with potential volatility to monitor closely.
3. Robust Market Potential: The global CB market is expected to grow from $13.4B to over $148B by 2031, indicating a significant increase in demand and market size.
4. Strategic Global Partnerships: Akanda Corp. (NASDAQ: AKAN)’s portfolio includes CanMart, a UK-based pharmaceutical importer and distributor, and partnerships with entities like Cellen Life Sciences' Leva Clinic, enhancing its reach and credibility.
5. Expansion into Canada: The acquisition of a Canadian farming property in British Columbia, with plans to develop CB facilities, signifies Akanda Corp. (NASDAQ: AKAN)’s growth and diversification in North America.
6. German Market Entry: With Germany LGLizing CBPM, Akanda Corp. (NASDAQ: AKAN) is evaluating strategic moves and acquisitions in a market projected to reach over $5.7B by 2030, providing a substantial growth avenue.
7. US Market Positioning: Akanda Corp. (NASDAQ: AKAN) is preparing to capitalize on the anticipated rescheduling of CBPM as a Schedule III substance in the US, which could lead to favorable changes in market conditions and regulatory environment.
With an ultra-low float of less than 1.9M shares, Akanda Corp. (NASDAQ: AKAN) has the potential for significant price swings as demand shifts. As a nano-cap company with a market cap of under $3M (as of 8/1/2024), Akanda can experience rapid valuation changes compared to larger companies.
Akanda Corp. (NASDAQ: AKAN)’s strategic global partnerships, including CanMart in the UK and collaborations with entities like Cellen Life Sciences' Leva Clinic, bolster its reach and credibility. The company's expansion into Canada with a new farming property in British Columbia for developing CB facilities signifies its growth and diversification in North America.
In Germany, where the CBPM market is projected to reach over $5.7B by 2030, Akanda is evaluating strategic growth potential and acquisitions. Additionally, the company is preparing to capitalize on the anticipated rescheduling of CBPM as a Schedule III substance in the US, which could lead to favorable regulatory changes.
The global CBPM market is expected to grow from $13.4B to $148.9B by 2031, offering robust market potential. With experienced leadership and pioneering initiatives like setting up state-controlled CBPM shops in Germany for scientific purposes, Akanda is poised for significant growth.
Don’t miss out—immediately start your research on Akanda Corp. (NASDAQ: AKAN).
I mean it, Akanda Corp. (NASDAQ: AKAN) has a very small float so you’ll need to be ready early.
Pull up (AKAN) and add it to the top of your watchlist right now.
I’ll check back with you shortly.
| 
No comments:
Post a Comment